Vicore initiates human forearm blood flow study with C21
- Forearm blood flow is a technique to measure vasodilation and blood flow in man
- If successful, this will allow a faster and more accurate development of new ATRAG molecules
- Study approved by the Swedish Medical Products Agency and planned to start in Q2 2022
Gothenburg, March 18, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing angiotensin II type 2 receptor agonists (ATRAGs), today announces initiating a clinical trial with C21* using a method for measuring human forearm blood flow in healthy volunteers.
As part of the development of new ATRAGs for novel diseases, Vicore is developing a simple method for early dose finding of angiotensin II type 2 receptor (AT2R) stimulation in man. If successful, gaining confidence in an effective dose could increase probability of success in phase 2/3 and more streamlined and less resource intensive development programs. “With all clinical data now being generated with the lead molecule C21, it is a great advantage to have a clinical model to directly compare doses and effects” says Johan Raud, CSO of Vicore.
About angiotensin II type 2 receptor agonists (ATRAGs)
The AT2R is part of the body’s regeneration and repair system and is suggested to be involved in several diseases connected to ageing and cell senescence including idiopathic pulmonary fibrosis, chronic kidney disease, heart failure and cognitive disorders. Stimulating the AT2R has been shown to be effective in several disease models and the clinical validation is under way in acute and chronic lung disease. Stimulation of the AT2R can also dilate small resistance vessels in animals and man to locally increase blood flow.
For further information, please contact:
Carl-Johan Dalsgaard, CEO
Phone: +46 70 975 98 63
E-mail: carl-johan.dalsgaard@vicorepharma.com
This information was submitted for publication on March 18, 2022 at 08:00 CET.
About Vicore Pharma Holding AB (publ)
Vicore is a clinical-stage pharmaceutical company focused on developing innovative medicines in severe lung diseases where the Angiotensin II type 2 receptor (AT2R) plays an important role. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH) and COVID-19. VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.
The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.